GPCR Overview
Upcoming Projects (GPCR)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (GPCR)
-
A Third Opinion: Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 13, 2024 at 03:10 PM EDT -
A Second Opinion: Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 11, 2024 at 01:00 PM EDT -
Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 10, 2024 at 03:00 PM EDT -
A Third Look: Examining Structure Therapeutics' GLP-1 candidate GSBR-1290 and the results from its phase 1b clinical trial in type 2 diabetes.
Ticker: GPCR
Executed On: Oct 27, 2023 at 11:30 AM EDT -
A Second Look: Examining Structure Therapeutics' GLP-1 candidate GSBR-1290 and the results from its phase 1b clinical trial in type 2 diabetes.
Ticker: GPCR
Executed On: Oct 25, 2023 at 01:00 PM EDT -
Examining Structure Therapeutics' GLP-1 candidate GSBR-1290 and the results from its phase 1b clinical trial in type 2 diabetes.
Ticker: GPCR
Executed On: Oct 05, 2023 at 01:45 PM EDT
Upcoming & Overdue Catalysts (GPCR)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (GPCR)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
